Sanofi Goes All In For Type 1 Diabetes With Provention Buy
Tzield Was Approved In US In November
Executive Summary
Sanofi is taking full control of the recently approved type 1 diabetes prevention therapy Tzield by splashing out $2.9bn to acquire partner Provention.
You may also be interested in...
The ‘Biggest’ Dealmakers Of 2023 Were Not The Busiest
Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.
Sanofi Adds To Immunology Pipeline In Collaboration With Recludix
French pharma gets global rights at the start of Phase II for the US biotech’s preclinical program for inhibiting the STAT6 protein in respiratory and dermatologic disorders.
Pfizer/Seagen Merger Seems Set To Clear As US FTC Sticks To Traditional Review
Pink Sheet infographic breaks down the big pharma deals and required divestitures over the past four years. Seagen reports that Pfizer's acquisition of the company is expected to close late this year or in early 2024.